Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment Article Swipe
Related Concepts
Edward Gane
,
Eric Lawitz
,
David Pugatch
,
George Papatheodoridis
,
Norbert Bräu
,
Ashley Brown
,
Stanislas Pol
,
Vincent Leroy
,
Marcello Persico
,
Christophe Moreno
,
Massimo Colombo
,
Eric M. Yoshida
,
David R. Nelson
,
Christine A. Collins
,
Lei Yang
,
Matthew P. Kosloski
,
Federico Mensa
·
YOU?
·
· 2017
· Open Access
·
· DOI: https://doi.org/10.1056/nejmoa1704053
· OA: W2761085897
YOU?
·
· 2017
· Open Access
·
· DOI: https://doi.org/10.1056/nejmoa1704053
· OA: W2761085897
Treatment with glecaprevir and pibrentasvir for 12 weeks resulted in a high rate of sustained virologic response in patients with stage 4 or 5 chronic kidney disease and HCV infection. (Funded by AbbVie; ClinicalTrials.gov number, NCT02651194 .).
Related Topics
Finding more related topics…